New vaccines for tuberculosis (Q37757648)

22 August 2017

1 reference

title

New vaccines for tuberculosis (English)

1 reference

22 August 2017

0 references

Stefan H E Kaufmann

1

0 references

author name string

Gregory Hussey

series ordinal

2

1 reference

PubMed ID

20488515

22 August 2017

Paul-Henri Lambert

series ordinal

3

1 reference

PubMed ID

20488515

22 August 2017

language of work or name

English

0 references

publication date

18 May 2010

1 reference

22 August 2017

1 reference

22 August 2017

375

1 reference

22 August 2017

2110-2119

1 reference

22 August 2017

9731

1 reference

Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis

22 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

Envisioning future strategies for vaccination against tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

Recent findings in immunology give tuberculosis vaccines a new boost

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

The Development and Impact of Tuberculosis Vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

New insights into the function of granulomas in human tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

Immunology's foundation: the 100-year anniversary of the Nobel Prize to Paul Ehrlich and Elie Metchnikoff

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

The contribution of immunology to the rational design of novel antibacterial vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

Toll or toll-free adjuvant path toward the optimal vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

Cell-mediated immune responses in tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

Who puts the tubercle in tuberculosis?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

M. tuberculosis and M. leprae Translocate from the Phagolysosome to the Cytosol in Myeloid Cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

No life without death--apoptosis as prerequisite for T cell activation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

The expanding universe of T-cell subsets: Th1, Th2 and more.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

Fine-tuning of T cell responses during infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

Pathogen recognition and innate immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

1 reference

7 January 2021

Regulatory T cells in the control of host-microorganism interactions (*).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

An antimicrobial activity of cytolytic T cells mediated by granulysin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

Effector and memory CTL differentiation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

Central memory and effector memory T cell subsets: function, generation, and maintenance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

Th1 memory: implications for vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

T-cell homing specificity and plasticity: new concepts and future challenges

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

PD-1 and its ligands in tolerance and immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

BCG and HIV reconsidered: moving the research agenda forward

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

HIV-1 infection in infants severely impairs the immune response induced by Bacille Calmette-Guérin vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

Variation in protection by BCG: implications of and for heterologous immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

Geographic latitude and the efficacy of bacillus Calmette-Guérin vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

The influence of previous exposure to environmental mycobacteria on the interferon-gamma response to bacille Calmette-Guérin vaccination in southern England and northern Malawi.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

The potential impact of helminth infection on trials of novel tuberculosis vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

Nonreplicating persistence of mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

A Replication-Limited Recombinant Mycobacterium bovis BCG vaccine against tuberculosis designed for human immunodeficiency virus-positive persons is safer and more efficacious than BCG.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

Apoptotic vesicles crossprime CD8 T cells and protect against tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

Innate immune recognition of infected apoptotic cells directs T(H)17 cell differentiation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

Mycobacterium tuberculosis DeltaRD1 DeltapanCD: a safe and limited replicating mutant strain that protects immunocompetent and immunocompromised mice against experimental tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

IC31 and IC30, novel types of vaccine adjuvant based on peptide delivery systems

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

TB vaccines: current status and future perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

The candidate tuberculosis vaccine Mtb72F/AS02A: Tolerability and immunogenicity in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

Development of nonhuman adenoviruses as vaccine vectors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

Identification of a heparin-binding hemagglutinin present in mycobacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

The heparin-binding haemagglutinin of M. tuberculosis is required for extrapulmonary dissemination.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

Subcutaneous boosting with heparin binding haemagglutinin increases BCG-induced protection against tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

Heparin-binding hemagglutinin, from an extrapulmonary dissemination factor to a powerful diagnostic and protective antigen against tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

Immunological consequences of three doses of heat-killed Mycobacterium vaccae in the immunotherapy of tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

Prevention of tuberculosis in Bacille Calmette-Guérin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

RUTI: a new chance to shorten the treatment of latent tuberculosis infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

Double-blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

Not to wake a sleeping giant: new insights into host-pathogen interactions identify new targets for vaccination against latent Mycobacterium tuberculosis infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

The quest for biomarkers in tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

Development of new tuberculosis vaccines: a global perspective on regulatory issues

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

Evaluation of the quality of informed consent in a vaccine field trial in a developing country setting

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

Changing funding patterns in tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

Eliminating human tuberculosis in the twenty-first century

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960393-5

7 January 2021

10.1016/S0140-6736(10)60393-5

Identifiers

DOI

1 reference

22 August 2017

1 reference

PubMed ID

20488515